Shire Plans New Cinryze Versions, Promises Fresh M&A And Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire ended 2013 on a high note with promises to keep up its fast but disciplined pace to generate strong profits and cash for use in fresh drug innovation and further M&A activity.
You may also be interested in...
Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.